(6 Aug. 2026) Recently, Global Banking and Finance Review, a leading British financial magazine, announced its 2026 award winners. Fosun International Limited (HKEX stock code: 00656) received three awards in recognition of its outstanding contributions to sustainable development and corporate social responsibility (CSR), as well as its growing global brand influence.

On 29th July, Fosun International (00656.HK) issued a positive profit alert. Its profit attributable to owners of the parent for the first half of 2026 is expected to range from approximately RMB1.5 billion to RMB1.8 billion representing an increase of approximately 127% to 172% compared to the same period last year. The board of directors (the “Board”) considers that such increase is mainly attributable to the strong resilience demonstrated by its core industries in the first half of 2026, the steady improvement in operational quality, and the significant increase in industrial operation profit compared to the same period last year.

On 30 June 2026, Corporate Governance Asia presented the 16th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International Limited (“Fosun International”, “Fosun” or the “Group”) (HKEX stock code: 00656) were both honored with Asia’s Best CEO. In addition, Fosun International received Sustainable Asia Award 2026, Best Environmental Responsibility Award and Best Corporate Communications Award.

The most authoritative corporate governance magazine in the Asia Pacific region, Corporate Governance Asia, has recently presented the 16th Asian Excellence Award. Chen Qiyu and Xu Xiaoliang, Executive Directors and Co-CEOs of Fosun International, were awarded Asia’s Best CEO by the magazine.

Shanghai, June 9, 2026 — Henlius (2696.HK) announced that the New Drug Application (NDA) for a new indication of its self-developed anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab, trade name in Europe: Hetronifly^®) , in combination with Oxaliplatin and S-1 for neoadjuvant treatment of resectable gastric cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy after surgery, has been officially approved by the China National Medical Products Administration (NMPA) under the priority review pathway.

On May 29, 2026, Henlius (2696.HK) announced that the New Drug Application (NDA) for its independently developed pertuzumab biosimilar HANBEIYOU (trade name in US and Europe: POHERDY^®) has been approved by the National Medical Products Administration (NMPA). It is indicated for neoadjuvant and adjuvant treatment of HER2-positive early-stage breast cancer and for the treatment of metastatic breast cancer, covering all indications approved in the Chinese Mainland for the reference pertuzumab injection. The approval signifies that the product has now been approved in the three major markets of China, the European Union, and the United States. Furthermore, Henlius' HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe) and HANBEIYOU have become the first domestic trastuzumab-pertuzumab dual-target combination approved in China, the US, and the EU. This critical milestone further solidifies the company's leading position in the comprehensive, full-course and global layout in the field of breast cancer treatment.

On 27 May 2026, Fortune China magazine released its 2026 list of “Most Admired Chinese Companies”, in which Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was included in the Industry Star List. This highlights Fosun’s outstanding performance and industry leadership in environmental, social, and corporate governance (ESG), employee responsibility, and value creation for stakeholders.

On 21 May 2026, S&P Global hosted the “Sustainability Yearbook (China Edition) 2026 Launch Ceremony and Sustainability Forum” in Shanghai. Fosun International Limited (Hong Kong Stock Exchange stock code: 00656, “Fosun International”) was included in the S&P Global Sustainability Yearbook (China Edition) 2026 and ranked among China’s Top 1% for the third consecutive year, recognizing its long-standing commitment to advancing environmental, social and governance (ESG) practices. This achievement underscores Fosun International’s industry-leading position in sustainability management and ESG efforts.

(Shanghai, China and Seongnam-si, South Korea, 13 May, 2026) – On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. (“AriBio”), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer’s disease (AD).